Phacotrabeculectomy Versus Phacogoniotomy (PVP) in Advanced Primary Angle-closure Glaucoma

  • End date
    Jun 30, 2025
  • participants needed
  • sponsor
    Sun Yat-sen University
Updated on 17 September 2021


A multicenter, parallel, open, non-inferior randomized controlled trial was conducted to compare the effectiveness and safety of phacotrabeculectomy and phacogoniotomy in the treatment of advanced primary angle closure glaucoma, so as to provide a better surgical alternative.


Glaucoma is the leading cause of irreversible blindness worldwide, and primary angle closure glaucoma (PACG) accounted for the majority particularly in Asia and China. The preferred treatment method is anti-glaucoma surgery-trabeculectomy (Trab) combined with lens extraction. Phacotrabeculectomy has become the first-line choice of anti-glaucoma suregery in the treatment of advanced PACG. However, it was not an ideal method due to the bleb-related complications and troublesome postoperative nursing, as well as the difficulty for surgeons, caused by trabeculectomy. However, recent studies revealed that the phacoemulsification with intraocular lens implantation (PEI) combined with goniosynechialysis (GSL) has achieved efficacy in the treatment of PACG.

With the advent of minimally invasive glaucoma surgeries (MIGS), there is an increasing number studies indicating the MIGS performed great efficacy in the treatment of primary open angle glaucoma. While,there were a few small-sampled retrospective studies which showed therapeutic effects in PACG. The GSL plus goniotomy (GT) could achieve great efficacy in lowering the intraocular pressure of PACG patients. However, there is still a lack of high quality and high-level randomized controlled trials.

Therefore, this study intends to conduct a multicenter, parallel, open, non-inferior randomized controlled trial to compare the effectiveness and safety of PEI+ Trab and PEI+GSL+GT in the treatment of advanced PACG, so as to provide a better surgical treatment for PACG.

Condition Angle Closure Glaucoma
Treatment phacoemulsification with intraocular lens implantation combined with goniosynechialysis and goniotomy, phacoemulsification with intraocular lens implantation combined with trabeculectomy
Clinical Study IdentifierNCT04878458
SponsorSun Yat-sen University
Last Modified on17 September 2021


Yes No Not Sure

Inclusion Criteria

Aged 40-80
Diagnosed with advanced PACG
meet with (1) (2) (3) or (1) (2) (4) (1) more than 180-degree synechial
closure of anterior chamber angle on gonioscopy; (2) IOP> 21mmHg (Goldmann
applanation), with or without anti-glaucoma medication; (3) Significant
glaucomatous optic neuropathy [cup-to-disc (C/D)ratio0.7, or C/D asymmetry >
2, or the rim width at superior and inferior temporal < 0.1 vertical
diameters of optic disc); (4) With glaucoma visual field defects, such as
nasal step, arcurat defect, and paracentral scotoma (on reliable Humphrey
analyzer using SITA-Standard 24-2 or 30-2 algorithm); mead deviation -12dB)
\. Patients with clinically significant cataracts with a visual acuity of
less than 0.63 (ETDRS LogMAR), or need lens extraction assessed by an
\. Patients voluntarily participated in the study with signed informed
consent and agreed to follow up according to the study plan

Exclusion Criteria

History of intraocular surgery or ocular trauma (other than laser iridotomy or laser iriplasty)
Concomitant with other types of glaucoma, including: primary open-angle glaucoma, various types of secondary glaucoma (secondary angle-closure glaucoma, steroidal glaucoma, secondary angle regression glaucoma, neovascular glaucoma, inflammatory secondary glaucoma, true microophthalmia, pseudoextirpation syndrome, etc.)
The International Standardized Ratio (INR) > 3.0 for patients receiving warfarin or anticoagulant therapy before surgery
People with fundus disease that affects the collection of eye parameters or interferes with visual field examination
Long-term local or systemic use of glucocorticoids
Cyclops (corrected visual acuity less than 0.01 in non-study eyes)
Complicated with serious systemic diseases
Pregnant or lactating women
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note